← Back to all signals
RESEARCH PAPER ANALYSIS

Nurse-led management of sialorrhea in Parkinson's disease: a pilot randomized controlled trial.

A pilot randomized single-center trial (n=80) found that a nurse-led, Theory of Symptom Management–based home program reduced sialorrhea severity and improved self-management in Parkinson's patients after four weeks compared with control.

PMID41939767
JournalFrontiers in medicine
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

A pilot randomized single-center trial (n=80) found that a nurse-led, Theory of Symptom Management–based home program reduced sialorrhea severity and improved self-management in Parkinson's patients after four weeks compared with control.

WHY IT MATTERS

Research significance

This study provides pragmatic, scalable evidence for improving a bothersome PD non-motor symptom and quality of life through behavioral/nursing care, but offers limited mechanistic or drug-discovery insights for therapeutic development.

ABSTRACT

Source abstract

BACKGROUND: One of the most prevalent non-motor symptoms in people with Parkinson's disease (PD) is sialorrhea. In addition to aggravating pre-existing swallowing and speech issues, sialorrhea frequently causes perioral dermatitis, choking episodes, and aspiration pneumonia. In extreme situations, patients are forced to carry handkerchiefs at all times, which not only damages their reputation and results in social embarrassment and isolation, but also initiates or intensifies psychiatric symptoms like sadness and anxiety. Current management of PD-related sialorrhea includes pharmacological treatments, botulinum toxin, and behavioral strategies. While interventions such as speech therapy and oral exercises are effective, they are often applied episodically in clinical settings. Consequently, patients struggle to sustain these techniques daily. Addressing the lack of integrated nursing protocols for continuous home-based application, this study aimed to develop a structured sialorrhea management program based on the Theory of Symptom Management (SMT) and evaluate its feasibility and preliminary effectiveness. METHODS: Based on SMT, an intervention was constructed via expert Delphi consultations. Subsequently, 80 patients with PD-related sialorrhea were randomized into control or intervention groups in a single-center trial. Efficacy was evaluated after four weeks based on sialorrhea severity and self-management capacity. RESULTS: We created an intervention framework with 13 secondary indicators, 39 tertiary indicators, and three primary indicators (symptom experience, symptom management strategies, and symptom management results) after two rounds of Delphi expert consultation. Following the four-week intervention, the intervention group demonstrated significantly lower scores on the Sialorrhea Clinical Scale for PD and the sialorrhea-related item of the Unified PD Rating Scale than the control group (P < 0.05). Furthermore, the intervention group achieved a significantly higher score in self-management ability compared to the control group (P < 0.05). CONCLUSIONS: As a structured approach designed to eventually improve quality of life, this sialorrhea intervention program provides preliminary evidence of feasibility and early efficacy in reducing symptom severity and bolstering self-management. CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/index.html, ChiCTR2500096034.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic